

Resource Summary Report

Generated by [dkNET](#) on Sep 6, 2026

PLC/PRF/5

RRID:CVCL_0485

Type: Cell Line

Proper Citation

RRID:CVCL_0485

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0485

Proper Citation: RRID:CVCL_0485

Description: Cell line PLC/PRF/5 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult hepatocellular carcinoma

Defining Citation: [PMID:63998](#), [PMID:184551](#), [PMID:187208](#), [PMID:1317878](#), [PMID:1661347](#), [PMID:2414854](#), [PMID:2439335](#), [PMID:2542205](#), [PMID:2992761](#), [PMID:2992762](#), [PMID:3023526](#), [PMID:3431441](#), [PMID:6160110](#), [PMID:6225510](#), [PMID:6248960](#), [PMID:6268737](#), [PMID:6275024](#), [PMID:6288577](#), [PMID:6302689](#), [PMID:6317496](#), [PMID:6555060](#), [PMID:6889516](#), [PMID:7874267](#), [PMID:8050184](#), [PMID:8224613](#), [PMID:8389256](#), [PMID:8835345](#), [PMID:9023415](#), [PMID:9178645](#), [PMID:9290701](#), [PMID:9359923](#), [PMID:10523694](#), [PMID:11050057](#), [PMID:12029633](#), [PMID:15767549](#), [PMID:20069059](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23505090](#), [PMID:23887712](#), [PMID:25485619](#), [PMID:25574106](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:29892436](#), [PMID:30894373](#), [PMID:31063779](#), [PMID:31068700](#), [PMID:31378681](#)

Comments: Caution: Often called PLC8024 in Chinese literature probably because of a concatenation between PLC/PRF/5 and ATCC-8024., Karyotypic information: Has lost chromosome Y., Virology: Susceptible to infection by adenovirus types 40 (Ad40) and 41 (Ad41) (PubMed=1317878)., Virology: Contains at least 7 copies of integrated hepatitis B virus (HBV) genomes. Secretes hepatitis virus B surface antigen (HBsAg) but no other HBV proteins (PubMed=6302689; PubMed=6317496)., Population: African; Shangaan., Part of: MD Anderson Cell Lines Project., Part of: Liver Cancer Model Repository (LIMORE)., Part of: JFCR45 cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: PLC/PRF/5

Synonyms: PLC-PRF-5, PLC PRF 5, PLC/PRF5, PLCPRF5, PLC-8024, PLC8024, PLC, Alexander cells, Alexander, Primary Liver Carcinoma/Poliomyelitis Research Foundation/5

Cross References: BTO:BTO_0003492, CLO:CLO_0008458, CLO:CLO_0008459, EFO:EFO_0006291, MCCL:MCC:0000384, CLDB:cl3914, CLDB:cl3915, CLDB:cl3916, CLDB:cl5248, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:CRL-8024, BCRC:60223, BCRJ:0274, BioGRID_ORCS_Cell_line:484, BioSample:SAMN03471130, BioSample:SAMN03473236, BioSample:SAMN10988112, cancercellines:CVCL_0485, CCRID:1101HUM-PUMC000674, CCRID:1102HUM-NIFDC00071, CCRID:3101HUMTCHu119, CCRID:4201HUM-CCTCC00644, Cell_Model_Passport:SIDM01318, CGH-DB:9070-4, ChEMBL-Cells:ChEMBL3308140, ChEMBL-Targets:ChEMBL1075561, CLS:300315, Cosmic:721061, Cosmic:808505, Cosmic:871514, Cosmic:873402, Cosmic:925349, Cosmic:945155, Cosmic:948065, Cosmic:1019318, Cosmic:1351513, Cosmic:1518224, Cosmic:2023861, Cosmic:2162538, Cosmic:2321033, Cosmic:2674231, Cosmic:2773187, DepMap:ACH-001318, ECACC:85061113, EGA:EGAS00001000610, GDSC:925349, GEO:GSM207051, GEO:GSM565881, GEO:GSM827153, GEO:GSM886865, GEO:GSM887520, GEO:GSM887930, GEO:GSM888602, GEO:GSM936773, GEO:GSM2551580, GEO:GSM2551581, IARC_TP53:107, IARC_TP53:30016, IZSLER:BS TCL 122, JCRB:IFO50069, JCRB:JCRB0406, KCB:KCB 200785YJ, KCLB:28024, LiGeA:CCLE_292, LIMORE:PLC8024, LIMORE:PLCPRF5, LINCS_LDP:LCL-1942, NCBI_Iran:C145, PharmacDB:PLCPRF5_1274_2019, Progenetix:CVCL_0485, PubChem_Cell_line:CVCL_0485, RCB:RCB1887, TKG:TKG 0376, TOKU-E:2898, Ubigen:YC-C125, Wikidata:Q54947574

ID: CVCL_0485

Record Creation Time: 20220427T221434+0000

Record Last Update: 20260905T182118+0000

Ratings and Alerts

No rating or validation information has been found for PLC/PRF/5.

Warning: Discontinued: RCB; RCB1887

Caution: Often called PLC8024 in Chinese literature probably because of a concatenation between PLC/PRF/5 and ATCC-8024., Karyotypic information: Has lost chromosome Y., Virology: Susceptible to infection by adenovirus types 40 (Ad40) and 41 (Ad41) (PubMed=1317878)., Virology: Contains at least 7 copies of integrated hepatitis B virus (HBV) genomes. Secretes hepatitis virus B surface antigen (HBsAg) but no other HBV proteins (PubMed=6302689; PubMed=6317496)., Population: African; Shangaan., Part of: MD Anderson Cell Lines Project., Part of: Liver Cancer Model Repository (LIMORE)., Part of: JFCR45 cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 590 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zheleznyak A, et al. (2026) Epithelial-Mesenchymal Transition and Stress Adaptations Underlie Yttrium-90 Resistance in Liver Cancer Cell Lines. Cancer research communications, 6(1), 178.

Yamane M, et al. (2026) H4K5 lactylation - ENO2 loop drives glycolysis and HCC progression. JHEP reports : innovation in hepatology, 8(5), 101786.

Guo WW, et al. (2026) CCT2 Orchestrates Glycolysis and Exosome-Mediated M2 Macrophage Polarization in HCC tumorigenesis. International journal of biological sciences, 22(7), 3389.

Ai ZE, et al. (2026) Targeting ADAR1 p150 triggers tumor inhibition and antitumor immunity to overcome immunotherapy resistance. iScience, 29(6), 115978.

Wang Y, et al. (2026) NAT10 drives hepatocellular carcinoma progression through SQLE-mediated cholesterol biosynthesis and is targetable by remodelin. iScience, 29(1), 114488.

Chen X, et al. (2026) Nutrient Restriction Improves the Therapeutic Efficacy of Sorafenib by Inducing Ferroptosis via the NRF2/HO-1/GPX4 Pathway in Hepatocellular Carcinoma. Journal of hepatocellular carcinoma, 13, 572919.

Guo Z, et al. (2026) RASGEF1B suppresses hepatocellular carcinoma through the ALDH7A1/Betaine/SNAI1 metabolic/epigenetic axis. Journal of translational medicine, 24(1).

Hu Z, et al. (2026) Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors. Immunity, 59(7), 1928.

Zhang J, et al. (2026) Hepatocyte BPGM Induces RET Lactylation and Macrophage Reprogramming to Promote Tumorigenesis in Hepatocellular Carcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e18180.

Montoya T, et al. (2026) Alanine catabolism as a targetable vulnerability for MYC-driven liver cancer. Cell reports, 45(4), 117107.

Adan-Villaescusa E, et al. (2026) Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma. Cell reports. Medicine, 7(4), 102717.

Jang SH, et al. (2026) Epigenetic silencing of the liver-specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation. *Molecular oncology*.

Xu M, et al. (2026) UFMylation Suppresses Hepatocellular Carcinoma Metastasis by Inhibiting β -Catenin-Driven Hybrid EMT and NK Cell Evasion. *Cancer research*, 86(13), 3213.

Wang LT, et al. (2026) ISX-TWIST1 reprograms CD47-inflammasome signaling to reshape the immune microenvironment in liver cancer. *Experimental hematology & oncology*, 15(1).

Fang C, et al. (2026) Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. *Cancer research*, 86(8), 1956.

Huang YS, et al. (2026) Phenotypic Response Surfaces-Guided Optimization (PRS-OPT) of Propolis-Metformin-Regorafenib Combination Therapy for MASLD-Associated Hepatocellular Carcinoma. *Oncology research*, 34(6), 25.

Liu K, et al. (2026) Hypoxia-driven lncRNA SHIELD promotes GPX4 translation and protects against ferroptosis in hepatocellular carcinoma. *Molecular cell*, 86(11), 2106.

Wang Y, et al. (2025) cGAS Inhibits ALDH2 to Suppress Lipid Droplet Function and Regulate MASLD Progression. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(46), e08576.

Dong Z, et al. (2025) The LUBAC subunit HOIL-1 promotes the progression of HBV-associated hepatocellular carcinoma independently of linear ubiquitination. *Experimental & molecular medicine*, 57(10), 2317.

Yasukawa K, et al. (2025) ACVR2A attenuation impacts lactate production and hyperglycolytic conditions attracting regulatory T cells in hepatocellular carcinoma. *Cell reports. Medicine*, 6(4), 102038.